Altasciences has significant experience in cannabis, nicotine and tobacco product studies, both in the U.S. and Canada. We are invited members of the CORESTA (Cooperation Center for Scientific Research Relative to Tobacco) subcommittee on Smoking Behavior and Biomarkers, where we actively contribute to white papers concerning the latest requirements for clinical pharmacology studies needed for regulatory submission.
Since 2016, we have conducted more than 10 studies on electronic nicotine delivery systems (ENDS) or heat-not-burn products, with endpoints ranging from abuse potential, nicotine pharmacokinetics, and biomarkers of exposure and harm, to topography. Our clinics have specially-designed smoking rooms with dedicated air handling systems, as well as robust databases of participants who smoke and/or vape.
Our bioanalytical lab has been analyzing nicotine in blood and total urinary nicotine equivalents for years, and has developed a robust SOP for nicotine decontamination that ensures staff or participants do not contaminate the tubes. We recently validated the biomarkers of exposure, such as for tobacco specific nitrosamines (TSNAs).
- 60,000+ smokers in our database
- 10+ studies on vaping products since 2016
Our deep expertise and capabilities in a broad range of therapeutic areas encompasses preclinical and early clinical studies for both small molecules and biologics. We can manage your entire program, as well as provide comprehensive support research services and bioanalytical expertise.
Please see Therapeutic Areas for a fuller discussion of our capabilities and expertise.